Clinical Trials

February 21, 2014

Targeting the Right Ventricle in Pulmonary Hypertension  

  • Study Sponsor: Cardiovascular Medical Research and Education Fund
  • Institution: University of Pennsylvania
  • Start Date: 07/2013
  • End Date: 09/2015
  • Design: Placebo-controlled
  • Age range (years): from 18 to 80
  • Type of PH
    • All PAH (Group 1 PH)
    • IPAH
    • CTD - APAH
    • CHD - APAH
    • Heritable - APAH
    • CTEPH (Group 4)
  • Study Duration for individual patient: 26 weeks
  • Contact: Yuchi Han at 
  • Listing on


FacebookTwitterInstagram iconLinkedInYouTube

For optimal viewing of, please use a standards-compliant browser such as Google Chrome or Firefox.

The information provided on the PHA website is provided for general information only. It is not intended as legal, medical or other professional advice, and should not be relied upon as a substitute for consultations with qualified professionals who are familiar with your individual needs. PHA does not endorse or recommend any commercial products or services.

801 Roeder Road, Ste. 1000, Silver Spring, MD 20910   Patient-to-Patient Support Line: 1-800-748-7274
    Privacy Policy    Provide Feedback & Report Bugs

Designed by Matrix Group International, Inc.® | © 2016 Pulmonary Hypertension Association. All Rights Reserved.


The National Organization for Rare Disorders (NORD) awarded PHA the Abbey S. Meyers Leadership Award in 2012 for outstanding service to PHA members in advocacy, education and other key areas.